A Study of Imvotamab in Severe Systemic Lupus Erythematosus
Stopped early · Phase 1
Conditions studied: Systemic Lupus Erythematosus, Lupus Erythematosus
In brief
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with severe systemic lupus erythematosus who have failed prior therapies. Participants will be given imvotamab through a vein (i.e., intravenously).
Key facts
- Study ID
- NCT06041568
- Run by
- IGM Biosciences, Inc.
- People needed
- 17
- Starts
- 2023-08-15
- Expected to finish
- 2025-01-27
- Last updated by the study team
- 2025-02-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- TriWest Research Associates — San Diego, California, United States
- East Bay Rheumatology — San Leandro, California, United States
- Omega Research, DeBary — DeBary, Florida, United States
- Integral Rheumatology & Immunology Specialists — Plantation, Florida, United States
- Stryde Research — Allen, Texas, United States
- Precision Comprehensive Clinical Research — Grapevine, Texas, United States
- Prolato Clinical Research Center — Houston, Texas, United States
- Care and Cure Clinic — Houston, Texas, United States
- Niepubliczny Zakład Opieki Zdrowotnej Lecznica MAK-MED w Nadarzynie — Nadarzyn, Poland
- Seoul National University Hospital — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.